Helichrysetin

Helichrysetin

SCHEMBL2126372

COc1cc(O)cc(O)c1C(=O)/C=C/c1ccc(O)cc1

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.82
KMT2A Q03164 5/20 0.82
MEN1 O00255 4/20 0.82
NFKB1 P19838 1/20 0.82
DPP4 P27487 1/20 0.82
NFKB2 Q00653 1/20 0.82
RELA Q04206 1/20 0.82
KCNA3 P22001 1/20 0.82
NPSR1 Q6W5P4 1/20 0.82
ABCG2 Q9UNQ0 5/20 0.73
TDP1 Q9NUW8 3/20 0.72
CYP3A4 P08684 4/20 0.72
CHRNA7 P36544 1/20 0.72
SLC5A1 P13866 2/20 0.70
SLC5A2 P31639 2/20 0.70
TP53 P04637 2/20 0.67
ATM Q13315 1/20 0.67
HSD17B10 Q99714 1/20 0.67
MKNK2 Q9HBH9 1/20 0.67
KDM4E B2RXH2 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Helichrysetin SCHEMBL2126376 1.00 MAPT (0.82) MAPTKMT2AMEN1NFKB1DPP4
Helichrysetin SCHEMBL30382622 1.00 MAPT (0.82) MAPTKMT2AMEN1NFKB1DPP4
Helichrysetin SCHEMBL30383770 0.99 MAPT (0.80) MAPTKMT2AMEN1NFKB1DPP4
SCHEMBL4834940 0.93 TDP1 (0.83) MAPTKMT2AMEN1NFKB1DPP4
SCHEMBL4834935 0.93 TDP1 (0.83) MAPTKMT2AMEN1NFKB1DPP4
SCHEMBL2286236 0.92 ABCG2 (0.87) MAPTKMT2AMEN1NFKB1DPP4
SCHEMBL30383859 0.92 MAPT (0.78) MAPTKMT2AMEN1NFKB1DPP4
SCHEMBL2286389 0.92 MAPT (0.78) MAPTKMT2AMEN1NFKB1DPP4
SCHEMBL2286384 0.92 MAPT (0.78) MAPTKMT2AMEN1NFKB1DPP4
SCHEMBL30383887 0.92 ABCG2 (0.87) MAPTKMT2AMEN1NFKB1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338362-A1 METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS IATERION, INC, 2023-10-26 US claimed
EP-4213820-A1 METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS Iaterion, Inc. (US) 2023-07-26 EP claimed
WO-2022060822-A1 METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS IATERION, INC. (US) 2022-03-24 WO claimed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12419856-B1 Method of treating middle east respiratory syndrome (MERS) KING SAUD UNIVERSITY (SA) 2025-09-23 US disclosed
US-20250221944-A1 COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT KBLUEBIO INC (KR) 2025-07-10 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
CN-119837849-B Application of helichrysin in preparation of drugs for relieving and treating cell erythroid differentiation disorder of subjects 中国科学院北京基因组研究所(国家生物信息中心) 2025-06-13 CN disclosed
CN-119837849-A Application of helichrysin in preparation of drugs for relieving and treating cell erythroid differentiation disorder of subjects 中国科学院北京基因组研究所(国家生物信息中心) 2025-04-18 CN disclosed
EP-4506328-A1 COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT KBlueBio Inc (KR) 2025-02-12 EP disclosed
US-12208082-B1 Method of treating middle east respiratory syndrome (MERS) KING SAUD UNIVERSITY (SA) 2025-01-28 US disclosed
US-9061984-B2 Compounds related to chalcones and benzothienopyrimidines, their synthesis, and uses to treat diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2015-06-23 US disclosed
US-9061984-B2 Compounds related to chalcones and benzothienopyrimidines, their synthesis, and uses to treat diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2015-06-23 US disclosed
US-9061984-B2 Compounds related to chalcones and benzothienopyrimidines, their synthesis, and uses to treat diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2015-06-23 US disclosed
US-20120110703-A1 PROTEIN HAVING NOVEL PRENYLTRANSFERASE ACTIVITY AND GENE ENCODING THE SAME KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2012-05-03 US disclosed
EP-2444493-A1 PROTEIN HAVING NOVEL PRENYLATION ENZYME ACTIVITY AND GENE ENCODING SAME Kirin Holdings Kabushiki Kaisha (JP) 2012-04-25 EP disclosed
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES THE JOHNS HOPKINS UNIVERSITY 2011-08-04 US disclosed
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES THE JOHNS HOPKINS UNIVERSITY 2011-08-04 US disclosed
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES THE JOHNS HOPKINS UNIVERSITY 2011-08-04 US disclosed
WO-2010019861-A1 COMPOUNDS, THEIR SYNTHESES, AND THEIR USES UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338362-A1 METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS TREH, HAVCR2, CTRB1 MAPT 1732/4885KMT2A 3827/4885MEN1 796/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885KMT2A 2792/4885MEN1 3367/4885
US-12419856-B1 Method of treating middle east respiratory syndrome (MERS) SARS1, CKMT1A; CKMT1B, CHCHD6 MAPT 1401/4885KMT2A 2078/4885MEN1 1237/4885
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES TERT, TYMS, NISCH MAPT 2194/4885KMT2A 1587/4885MEN1 37/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885MEN1 2457/4885
US-12208082-B1 Method of treating middle east respiratory syndrome (MERS) SARS1, CKMT1A; CKMT1B, CHCHD6 MAPT 1401/4885KMT2A 2078/4885MEN1 1237/4885
US-20250221944-A1 COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT MCL1, CRBN, BCL3 MAPT 4100/4885KMT2A 1630/4885MEN1 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.